These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 30223226)

  • 1. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
    Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
    Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
    Forward DP; Cheung KL; Jackson L; Robertson JF
    Br J Cancer; 2004 Feb; 90(3):590-4. PubMed ID: 14760369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
    Tancredi R; Furlanetto J; Loibl S
    Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    Mehta RS; Barlow WE; Albain KS; Vandenberg TA; Dakhil SR; Tirumali NR; Lew DL; Hayes DF; Gralow JR; Linden HH; Livingston RB; Hortobagyi GN
    N Engl J Med; 2019 Mar; 380(13):1226-1234. PubMed ID: 30917258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
    Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
    Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
    J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.